Lumos Diagnostics Holdings Limited
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more
Lumos Diagnostics Holdings Limited (LDXHF) - Net Assets
Latest net assets as of December 2025: $5.24 Million USD
Based on the latest financial reports, Lumos Diagnostics Holdings Limited (LDXHF) has net assets worth $5.24 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.12 Million) and total liabilities ($15.88 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.24 Million |
| % of Total Assets | 24.79% |
| Annual Growth Rate | 10.95% |
| 5-Year Change | -89.44% |
| 10-Year Change | N/A |
| Growth Volatility | 123.04 |
Lumos Diagnostics Holdings Limited - Net Assets Trend (2018–2025)
This chart illustrates how Lumos Diagnostics Holdings Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lumos Diagnostics Holdings Limited (2018–2025)
The table below shows the annual net assets of Lumos Diagnostics Holdings Limited from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $6.16 Million | -13.39% |
| 2024-06-30 | $7.11 Million | -25.15% |
| 2023-06-30 | $9.50 Million | -46.89% |
| 2022-06-30 | $17.89 Million | -69.31% |
| 2021-06-30 | $58.28 Million | +163.68% |
| 2020-06-30 | $22.10 Million | +89.65% |
| 2019-06-30 | $11.65 Million | +291.71% |
| 2018-06-30 | $2.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lumos Diagnostics Holdings Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9780852100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $103.96 Million | 1688.53% |
| Other Comprehensive Income | $35.00K | 0.57% |
| Total Equity | $6.16 Million | 100.00% |
Lumos Diagnostics Holdings Limited Competitors by Market Cap
The table below lists competitors of Lumos Diagnostics Holdings Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nusantara Voucher Distribution Tbk PT
JK:DIVA
|
$6.09 Million |
|
Skycorp Solar Group Limited Ordinary Shares
NASDAQ:PN
|
$6.09 Million |
|
Enduro Metals Corporation
OTCQB:ENDMF
|
$6.09 Million |
|
Inter-Rock Minerals Inc
PINK:IRCKF
|
$6.09 Million |
|
NYRSTAR
F:3NY1
|
$6.09 Million |
|
Odonate Inc.
PINK:ODTCD
|
$6.09 Million |
|
Kurniamitra Duta Sentosa Tbk
JK:KMDS
|
$6.09 Million |
|
Aquaron Acquisition Corp. Common Stock
NASDAQ:AQU
|
$6.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lumos Diagnostics Holdings Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,109,000 to 6,157,000, a change of -952,000 (-13.4%).
- Net loss of 7,183,000 reduced equity.
- New share issuances of 6,222,000 increased equity.
- Other comprehensive income increased equity by 294,000.
- Other factors decreased equity by 285,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.18 Million | -116.66% |
| Share Issuances | $6.22 Million | +101.06% |
| Other Comprehensive Income | $294.00K | +4.78% |
| Other Changes | $-285.00K | -4.63% |
| Total Change | $- | -13.39% |
Book Value vs Market Value Analysis
This analysis compares Lumos Diagnostics Holdings Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.66x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.82x to 1.66x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-06-30 | $0.02 | $0.02 | x |
| 2019-06-30 | $0.07 | $0.02 | x |
| 2020-06-30 | $0.13 | $0.02 | x |
| 2021-06-30 | $0.34 | $0.02 | x |
| 2022-06-30 | $0.12 | $0.02 | x |
| 2023-06-30 | $0.04 | $0.02 | x |
| 2024-06-30 | $0.01 | $0.02 | x |
| 2025-06-30 | $0.01 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lumos Diagnostics Holdings Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -116.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -57.46%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 3.38x
- Recent ROE (-116.66%) is below the historical average (-92.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -42.49% | -65.98% | 0.22x | 2.98x | $-1.56 Million |
| 2019 | -39.41% | -102.57% | 0.18x | 2.18x | $-5.76 Million |
| 2020 | -41.89% | -160.15% | 0.19x | 1.37x | $-11.47 Million |
| 2021 | -25.95% | -79.72% | 0.19x | 1.68x | $-20.95 Million |
| 2022 | -255.66% | -393.16% | 0.31x | 2.07x | $-47.51 Million |
| 2023 | -93.52% | -84.31% | 0.41x | 2.68x | $-9.83 Million |
| 2024 | -120.86% | -77.19% | 0.41x | 3.78x | $-9.30 Million |
| 2025 | -116.66% | -57.46% | 0.60x | 3.38x | $-7.80 Million |
Industry Comparison
This section compares Lumos Diagnostics Holdings Limited's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lumos Diagnostics Holdings Limited (LDXHF) | $5.24 Million | -42.49% | 3.03x | $6.09 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |